U.S. vaccine manufacturer Novavax says it has successfully tested its Corona vaccine in adolescents between 12 and 17.
The drug’s efficacy was 82 percent, according to the results of a Phase 3 study, the manufacturer announced on Friday.
Study in adolescents on Novavax vaccine submitted
The study involved about 2,247 adolescents between the ages of 12 and 17 in the U.S. – but when the delta variant of the virus was still prevalent, not the omicron variant. The vaccination was well tolerated, they said.
Novavax said it would seek approval for this age group within the next few weeks. Novavax’s adult vaccine is already approved in Europe, and approval is under review in the United States.
- source: vienna.at/picture: aerzteblatt.de
This post has already been read 54 times!